Friday, May 1, 2026

Progressive and Conservative Inter-Korean Policies Both Rooted In “East-West German Basic Treaty”: An End to Consumptive Debates Is Needed

The Two States Theory debate highlights ideological divides without practical solutions, misusing the East-West Germany treaty as justification.

North Korea’s Latest Missile Launch: What You Need to Know About the 10 Ballistic Missiles Fired

North Korea launched over ten ballistic missiles, prompting an emergency review by South Korea's Office of National Security amid joint military exercises.

TREASON? Military Hid That Armed North Korean Soldiers INVADED South Korean Territory for Hours

A North Korean soldier defected, prompting armed troops to cross the MDL, leading to warning shots from South Korea.

Tag: ABL Bio

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

ABL209: The Promising Dual Antibody ADC Revolutionizing Cancer Treatment in 2026

ABL Bio's ABL209 shows promising anti-cancer effects with broad safety in preclinical studies, advancing to Phase 1 trials in the U.S.

FDA Grants Orphan Drug Status to Tovecimig: What This Means for Cholangiocarcinoma Treatment

ABL Bio's Tovecimig receives Orphan Drug Designation from the FDA, enhancing its approval prospects for cholangiocarcinoma treatment.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

Unlocking Cancer Treatment: ABL206 and ABL209’s Promising Non-Clinical Data Revealed at AACR

ABL Bio will present preclinical data for its ADCs ABL206 and ABL209 at AACR 2023, showcasing promising anti-cancer efficacy.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

How ABL Bio’s Grabody-B Revolutionizes siRNA Delivery: A Game-Changer for Brain Disease Treatment?

ABL Bio's Grabody-B technology effectively delivers siRNA across the blood-brain barrier, enhancing treatment for brain and systemic diseases.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.